Low Sensitivity of BinaxNOW RSV in Infants

RESCEU Investigators; Steven Cunningham

doi:10.1093/infdis/jiaa050

Low Sensitivity of BinaxNOW RSV in Infants

Research output: Contribution to journal › Article › peer-review

Abstract / Description of output

BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Early detection of RSV can optimize clinical management and minimize use of antibiotics. BinaxNOW RSV (BN) is a rapid antigen detection test that is widely used. We aimed to validate the sensitivity of BN in hospitalized and nonhospitalized infants against the gold standard of molecular diagnosis.

METHODS: We evaluated the performance of BN in infants with acute respiratory tract infections with different degrees of disease severity. Diagnostic accuracy of BN test results were compared with molecular diagnosis as reference standard.

RESULTS: One hundred sixty-two respiratory samples from 148 children from October 2017 to February 2019 were studied. Sixty-six (40.7%) samples tested positive for RSV (30 hospitalizations, 31 medically attended episodes not requiring hospitalization, and 5 nonmedically attended episodes). Five of these samples tested positive with BN, leading to an overall sensitivity of BN of 7.6% (95% confidence interval [CI], 3.3%-16.5%) and a specificity of 100% (95% CI, 96.2%-100%). Sensitivity was low in all subgroups.

CONCLUSIONS: We found a low sensitivity of BN for point-of-care detection of RSV infection. BinaxNOW RSV should be used and interpreted with caution.

Original language	English
Journal	The Journal of Infectious Diseases
Early online date	30 Mar 2020
DOIs	https://doi.org/10.1093/infdis/jiaa050
Publication status	E-pub ahead of print - 30 Mar 2020

Access to Document

10.1093/infdis/jiaa050

jiaa050
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact [email protected] DOI: 10.1093/infdis/jiaa050
Final published version, 206 KBLicence: Creative Commons: Attribution Non-Commercial (CC-BY-NC)

https://academic.oup.com/jid/advance-article/doi/10.1093/infdis/jiaa050/5813515

Cite this

@article{0d0cd9a06f544fe4991f0a40ef9e0ec4,

title = "Low Sensitivity of BinaxNOW RSV in Infants",

abstract = "BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Early detection of RSV can optimize clinical management and minimize use of antibiotics. BinaxNOW RSV (BN) is a rapid antigen detection test that is widely used. We aimed to validate the sensitivity of BN in hospitalized and nonhospitalized infants against the gold standard of molecular diagnosis.METHODS: We evaluated the performance of BN in infants with acute respiratory tract infections with different degrees of disease severity. Diagnostic accuracy of BN test results were compared with molecular diagnosis as reference standard.RESULTS: One hundred sixty-two respiratory samples from 148 children from October 2017 to February 2019 were studied. Sixty-six (40.7%) samples tested positive for RSV (30 hospitalizations, 31 medically attended episodes not requiring hospitalization, and 5 nonmedically attended episodes). Five of these samples tested positive with BN, leading to an overall sensitivity of BN of 7.6% (95% confidence interval [CI], 3.3%-16.5%) and a specificity of 100% (95% CI, 96.2%-100%). Sensitivity was low in all subgroups.CONCLUSIONS: We found a low sensitivity of BN for point-of-care detection of RSV infection. BinaxNOW RSV should be used and interpreted with caution.",

author = "{RESCEU Investigators} and Zuurbier, {Roy P} and Bont, {Louis J} and Langedijk, {Annefleur C} and Mirjam Hamer and Koos Korsten and Drysdale, {Simon B} and Snape, {Matthew D} and Hannah Robinson and Pollard, {Andrew J} and Federico Martin{\'o}n-Torres and {Rodr{\'i}guez-Tenreiro S{\'a}nchez}, Carmen and Alberto G{\'o}mez-Carballa and Dacosta-Urbieta, {Ana Isabel} and Terho Heikkinen and Steven Cunningham and {van Houten}, {Marlies A} and Wildenbeest, {Joanne G}",

note = "{\textcopyright} The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America.",

year = "2020",

month = mar,

day = "30",

doi = "10.1093/infdis/jiaa050",

language = "English",

journal = "The Journal of Infectious Diseases",

issn = "0022-1899",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Low Sensitivity of BinaxNOW RSV in Infants

AU - RESCEU Investigators

AU - Zuurbier, Roy P

AU - Bont, Louis J

AU - Langedijk, Annefleur C

AU - Hamer, Mirjam

AU - Korsten, Koos

AU - Drysdale, Simon B

AU - Snape, Matthew D

AU - Robinson, Hannah

AU - Pollard, Andrew J

AU - Martinón-Torres, Federico

AU - Rodríguez-Tenreiro Sánchez, Carmen

AU - Gómez-Carballa, Alberto

AU - Dacosta-Urbieta, Ana Isabel

AU - Heikkinen, Terho

AU - Cunningham, Steven

AU - van Houten, Marlies A

AU - Wildenbeest, Joanne G

PY - 2020/3/30

Y1 - 2020/3/30

N2 - BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Early detection of RSV can optimize clinical management and minimize use of antibiotics. BinaxNOW RSV (BN) is a rapid antigen detection test that is widely used. We aimed to validate the sensitivity of BN in hospitalized and nonhospitalized infants against the gold standard of molecular diagnosis.METHODS: We evaluated the performance of BN in infants with acute respiratory tract infections with different degrees of disease severity. Diagnostic accuracy of BN test results were compared with molecular diagnosis as reference standard.RESULTS: One hundred sixty-two respiratory samples from 148 children from October 2017 to February 2019 were studied. Sixty-six (40.7%) samples tested positive for RSV (30 hospitalizations, 31 medically attended episodes not requiring hospitalization, and 5 nonmedically attended episodes). Five of these samples tested positive with BN, leading to an overall sensitivity of BN of 7.6% (95% confidence interval [CI], 3.3%-16.5%) and a specificity of 100% (95% CI, 96.2%-100%). Sensitivity was low in all subgroups.CONCLUSIONS: We found a low sensitivity of BN for point-of-care detection of RSV infection. BinaxNOW RSV should be used and interpreted with caution.

AB - BACKGROUND: Respiratory syncytial virus (RSV) is a major cause of hospitalization in infants. Early detection of RSV can optimize clinical management and minimize use of antibiotics. BinaxNOW RSV (BN) is a rapid antigen detection test that is widely used. We aimed to validate the sensitivity of BN in hospitalized and nonhospitalized infants against the gold standard of molecular diagnosis.METHODS: We evaluated the performance of BN in infants with acute respiratory tract infections with different degrees of disease severity. Diagnostic accuracy of BN test results were compared with molecular diagnosis as reference standard.RESULTS: One hundred sixty-two respiratory samples from 148 children from October 2017 to February 2019 were studied. Sixty-six (40.7%) samples tested positive for RSV (30 hospitalizations, 31 medically attended episodes not requiring hospitalization, and 5 nonmedically attended episodes). Five of these samples tested positive with BN, leading to an overall sensitivity of BN of 7.6% (95% confidence interval [CI], 3.3%-16.5%) and a specificity of 100% (95% CI, 96.2%-100%). Sensitivity was low in all subgroups.CONCLUSIONS: We found a low sensitivity of BN for point-of-care detection of RSV infection. BinaxNOW RSV should be used and interpreted with caution.

U2 - 10.1093/infdis/jiaa050

DO - 10.1093/infdis/jiaa050

M3 - Article

C2 - 32227106

SN - 0022-1899

JO - The Journal of Infectious Diseases

JF - The Journal of Infectious Diseases

ER -

Low Sensitivity of BinaxNOW RSV in Infants

Abstract / Description of output

Access to Document

Fingerprint

Cite this